Artelo Biosciences Future Growth

Future criteria checks 0/6

Artelo Biosciences is forecast to grow earnings and revenue by 51.8% and 77.4% per annum respectively while EPS is expected to grow by 65.1% per annum.

Key information

51.8%

Earnings growth rate

65.1%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	77.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 Oct 2024

Recent future growth updates

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Earnings and Revenue Growth Forecasts

NasdaqCM:ARTL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-21	-18	-18	2
12/31/2025	N/A	-13	-10	-10	3
12/31/2024	N/A	-12	-17	-17	3
6/30/2024	N/A	-10	-9	-9	N/A
3/31/2024	N/A	-10	-9	-9	N/A
12/31/2023	N/A	-9	-8	-8	N/A
9/30/2023	N/A	-10	-8	-8	N/A
6/30/2023	N/A	-9	-8	-8	N/A
3/31/2023	N/A	-10	-8	-8	N/A
12/31/2022	N/A	-10	-8	-8	N/A
9/30/2022	N/A	-13	-9	-9	N/A
6/30/2022	N/A	-13	-9	-9	N/A
3/31/2022	N/A	-12	-8	-8	N/A
12/31/2021	N/A	-12	-8	-8	N/A
11/30/2021	N/A	-9	-7	-7	N/A
8/31/2021	N/A	-7	-6	-6	N/A
5/31/2021	N/A	-7	-5	-5	N/A
2/28/2021	N/A	-5	-5	-5	N/A
11/30/2020	N/A	-5	-5	-5	N/A
8/31/2020	N/A	-5	-4	-4	N/A
5/31/2020	N/A	-4	-6	-5	N/A
2/29/2020	N/A	-4	-6	-4	N/A
11/30/2019	N/A	-3	-5	-3	N/A
8/31/2019	N/A	-2	-4	-3	N/A
5/31/2019	N/A	-2	-2	-2	N/A
2/28/2019	N/A	-2	-2	-2	N/A
11/30/2018	N/A	-3	-2	-2	N/A
8/31/2018	N/A	-2	-2	-2	N/A
5/31/2018	N/A	-2	N/A	-1	N/A
2/28/2018	N/A	-1	N/A	-1	N/A
11/30/2017	N/A	-1	N/A	0	N/A
8/31/2017	N/A	0	N/A	0	N/A
5/31/2017	N/A	0	N/A	0	N/A
2/28/2017	N/A	0	N/A	0	N/A
11/30/2016	N/A	0	N/A	0	N/A
8/31/2016	N/A	0	N/A	0	N/A
5/31/2016	N/A	0	N/A	0	N/A
2/29/2016	N/A	0	N/A	0	N/A
11/30/2015	N/A	0	N/A	0	N/A
8/31/2015	N/A	0	N/A	0	N/A
5/31/2015	N/A	0	N/A	0	N/A
2/28/2015	N/A	0	N/A	0	N/A
11/30/2014	N/A	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARTL is forecast to have no revenue next year.

High Growth Revenue: ARTL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ARTL's Return on Equity is forecast to be high in 3 years time

Artelo Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 16% to US$35.00

Price target increased to US$57.50

Price target decreased to US$4.08

Recent updates

Insufficient new directors

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12

Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

New major risk - Revenue and earnings growth

New major risk - Financial position

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

New major risk - Revenue and earnings growth

Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11

Artelo Biosciences, Inc., Annual General Meeting, Jun 30, 2023

Price target decreased by 16% to US$35.00

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Price target increased to US$57.50

Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13

Artelo Biosciences, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$4.08

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences, Inc. Anticipates Accelerated Clinical Development for ART27.13

High number of new directors

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Independent Director John Beck has left the company

Relief For Cancer Patients In Artelo Bioscience Pipeline

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences, Inc. Appoints Tamara A. Seymour to its Board of Directors

Artelo Biosciences, Inc. Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

New 90-day high: US$1.28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

INO, VXRT, BTU and TTM among premarket gainers

Artelo Biosciences EPS misses by $0.04

New 90-day high: US$1.00

Artelo Biosciences, Inc. Appoints Gregory R. Reyes to the Company’s Board of Directors

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences on go with cancer appetite recovery study

New 90-day low: US$0.65

Artelo Biosciences, Inc. has completed a Composite Units Offering in the amount of $6.6 million.

Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

New 90-day low: US$0.71

New 90-day low - US$0.94

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies